Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD Up: Upadacitinib plus topical corticosteroids in moderate to severe atopic dermatitis
2022-502937-24-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Upadacitinib + topical corticosteroids with Placebo + topical corticosteroids (2 arms). Primary endpoints: vIGA-AD 0/1 with ≥2-grade reduction at Week 16 and EASI 75 at Week 16. Planned start Jan 2019; status: authorised.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-502937-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502937-24-00.